Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study-Reference-Cited by-同舟云学术

Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study

Published:2022-03 Issue: Volume:56 Page:100-111
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Calabrò Marco,Fabbri Chiara^ORCID,Kasper Siegfried,Zohar Joseph,Souery Daniel,Montgomery Stuart,Albani Diego,Forloni Gianluigi,Ferentinos Panagiotis^ORCID,Rujescu Dan,Mendlewicz Julien,De Ronchi Diana,Serretti Alessandro,Crisafulli Concetta

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference76 articles.

1. Pharmacogenetics Guidelines: overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines;Abdullah-Koolmees;Front Pharmacol,2020

2. Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam;Aoshima;Prog. Neuropsychopharmacol. Biol. Psychiatry,2003

3. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments;Arranz;Transl Psychiatry,2019

4. Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice;Bartova;World J. Biol. Psychiatry,2019

5. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder;Bishop;Pharmacogenet Genomics,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis;Translational Psychiatry;2024-07-19

2. Unraveling the Genetic Interplay and Therapeutic Potentials between Major Depressive Disorder and Metabolic Syndrome: Multi-Ancestry and Multi-Trait Genome-Wide Association Analyses;2024-04-01

3. Pharmacogenomic and pharmacometabolomic biomarkers of the efficacy and safety of antidepressants: focus on selective serotonin reuptake inhibitors;S.S. Korsakov Journal of Neurology and Psychiatry;2024

4. Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study;Biomedicines;2023-12-07

5. PharmGScore scores of compound genetic variant burden for psychiatric treatment optimization;2023-06-29